Literature DB >> 27348199

The Multiple Faces of Non-Cystic Fibrosis Bronchiectasis. A Cluster Analysis Approach.

Miguel Á Martínez-García1, Montserrat Vendrell2,3, Rosa Girón4, Luis Máiz-Carro5, David de la Rosa Carrillo6, Javier de Gracia3,7, Casilda Olveira8.   

Abstract

RATIONALE: The clinical presentation and prognosis of non-cystic fibrosis bronchiectasis are both very heterogeneous.
OBJECTIVES: To identify different clinical phenotypes for non-cystic fibrosis bronchiectasis and their impact on prognosis.
METHODS: Using a standardized protocol, we conducted a multicenter observational cohort study at six Spanish centers with patients diagnosed with non-cystic fibrosis bronchiectasis before December 31, 2005, with a 5-year follow-up from the bronchiectasis diagnosis. A cluster analysis was used to classify the patients into homogeneous groups by means of significant variables corresponding to different aspects of bronchiectasis (clinical phenotypes): age, sex, body mass index, smoking habit, dyspnea, macroscopic appearance of sputum, number of exacerbations, chronic colonization with Pseudomonas aeruginosa, FEV1, number of pulmonary lobes affected, idiopathic bronchiectasis, and associated chronic obstructive pulmonary disease. Survival analysis (Kaplan-Meier method and log-rank test) was used to evaluate the comparative survival of the different subgroups.
MEASUREMENTS AND MAIN RESULTS: A total of 468 patients with a mean age of 63 (15.9) years were analyzed. Of these, 58% were females, 39.7% had idiopathic bronchiectasis, and 29.3% presented with chronic Pseudomonas aeruginosa colonization. Cluster analysis showed four clinical phenotypes: (1) younger women with mild disease, (2) older women with mild disease, (3) older patients with severe disease who had frequent exacerbations, and (4) older patients with severe disease who did not have frequent exacerbations. The follow-up period was 54 months, during which there were 95 deaths. Mortality was low in the first and second groups (3.9% and 7.6%, respectively) and high for the third (37%) and fourth (40.8%) groups. The third cluster had a higher proportion of respiratory deaths than the fourth (77.8% vs. 34.4%; P < 0.001).
CONCLUSIONS: Using cluster analysis, it is possible to separate patients with bronchiectasis into distinct clinical phenotypes with different prognoses.

Entities:  

Keywords:  Pseudomonas aeruginosa; bronchiectasis; bronchiectasis exacerbation; cluster analysis; mortality

Mesh:

Year:  2016        PMID: 27348199     DOI: 10.1513/AnnalsATS.201510-678OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  16 in total

1.  Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Jonathan H Chung; Steven M Montner; Cathryn Lee; Leah J Witt; Danielle Stahlbaum; Rene S Bermea; Lena W Chen; Scully Hsu; Aliya N Husain; Imre Noth; Rekha Vij; Mary E Strek; Matthew Churpek
Journal:  Chest       Date:  2017-09-28       Impact factor: 9.410

2.  Exophiala dermatitidis Revealing Cystic Fibrosis in Adult Patients with Chronic Pulmonary Disease.

Authors:  Frédéric Grenouillet; Bernard Cimon; Heloise Pana-Katatali; Christine Person; Marie Gainet-Brun; Marie-Claire Malinge; Yohann Le Govic; Bénédicte Richaud-Thiriez; Jean-Philippe Bouchara
Journal:  Mycopathologia       Date:  2017-11-01       Impact factor: 2.574

3.  Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia.

Authors:  Justin P McCormick; Christopher G Weeks; Nicholas J Rivers; Jacob D Owen; David R Kelly; Steven M Rowe; George M Solomon; Bradford A Woodworth; Do-Yeon Cho
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-20       Impact factor: 3.858

4.  Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis.

Authors:  Miguel Ángel Martínez-García; Grace Oscullo; Alberto García-Ortega; Maria Gabriella Matera; Paola Rogliani; Mario Cazzola
Journal:  Drugs       Date:  2021-11-26       Impact factor: 9.546

Review 5.  The clinical phenotype of bronchiectasis and its clinical guiding implications.

Authors:  Li Gao; Ke-Ru Qin; Ting Li; Hai-Long Wang; Min Pang
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-26

6.  Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts.

Authors:  Rodrigo Athanazio; Mônica Corso Pereira; Georgina Gramblicka; Fernando Cavalcanti-Lundgren; Mara Fernandes de Figueiredo; Francisco Arancibia; Samia Rached; David de la Rosa; Luis Máiz-Carro; Rosa Girón; Casilda Olveira; Concepción Prados; Miguel Angel Martinez-Garcia
Journal:  BMC Pulm Med       Date:  2017-04-26       Impact factor: 3.317

7.  Predicting high risk of exacerbations in bronchiectasis: the E-FACED score.

Authors:  M A Martinez-Garcia; R A Athanazio; R Girón; L Máiz-Carro; D de la Rosa; C Olveira; J de Gracia; M Vendrell; C Prados-Sánchez; G Gramblicka; M Corso Pereira; F L Lundgren; M Fernandes De Figueiredo; F Arancibia; S Z Rached
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-01-18

Review 8.  Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis.

Authors:  Ravishankar Chandrasekaran; Micheál Mac Aogáin; James D Chalmers; Stuart J Elborn; Sanjay H Chotirmall
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

Review 9.  When and how ruling out cystic fibrosis in adult patients with bronchiectasis.

Authors:  Andrea Gramegna; Stefano Aliberti; Manuela Seia; Luigi Porcaro; Vera Bianchi; Carlo Castellani; Paola Melotti; Claudio Sorio; Enza Consalvo; Elisa Franceschi; Francesco Amati; Martina Contarini; Michele Gaffuri; Luca Roncoroni; Barbara Vigone; Angela Bellofiore; Cesare Del Monaco; Martina Oriano; Leonardo Terranova; Maria Francesca Patria; Paola Marchisio; Baroukh M Assael; Francesco Blasi
Journal:  Multidiscip Respir Med       Date:  2018-08-09

Review 10.  Bronchiectasis in the Last Five Years: New Developments.

Authors:  Jun Keng Khoo; Victoria Venning; Conroy Wong; Lata Jayaram
Journal:  J Clin Med       Date:  2016-12-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.